These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4668905)

  • 1. Effect of phosphate binging agents on bone remodelling in patients on regular haemodialysis.
    Fournier A; Tunchot S; Bedrossian J; Sionest JG; Idatte JM; Bordier P
    Proc Eur Dial Transplant Assoc; 1972; 9():126-41. PubMed ID: 4668905
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of phosphate-binders in patients on regular hemodialysis (author's transl)].
    Gahl G; Hopfenmüller W; Baethke R
    Med Klin; 1978 May; 73(19):710-4. PubMed ID: 651760
    [No Abstract]   [Full Text] [Related]  

  • 3. Total body calcium and long-term calcium balance in chronic renal disease.
    Denney JD; Sherrard DJ; Nelp WB; Chesnut CH; Baylink DJ
    J Lab Clin Med; 1973 Aug; 82(2):226-40. PubMed ID: 4721378
    [No Abstract]   [Full Text] [Related]  

  • 4. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis.
    Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL
    Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 7. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
    Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal osteopathy and bone mineralisation in patients treated with dihydrotachysterol during long term dialysis (author's transl)].
    Pogglitsch H; Schmidberger H; Gell G
    MMW Munch Med Wochenschr; 1976 Jan; 118(5):131-6. PubMed ID: 814443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of intestinal phosphate binders in patients maintained by hemodialysis.
    Johnson WJ; O'Brien PC
    Nephron; 1978; 21(3):123-30. PubMed ID: 673095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum parathyroid hormone concentration in chronic renal failure patients on maintenance haemodialysis.
    Wills MR; Fairney A; Varghese Z; Tatler GL; Baillod RA; Moorhead JF
    Clin Chim Acta; 1974 Nov; 57(1):83-9. PubMed ID: 4430145
    [No Abstract]   [Full Text] [Related]  

  • 11. Iatrogenic osteomalacia and myopathy due to phosphate depletion.
    Baker LR; Ackrill P; Cattell WR; Stamp TC; Watson L
    Br Med J; 1974 Jul; 3(5924):150-2. PubMed ID: 4843652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biochemical with radiological findings in renal osteodystrophy.
    Moorhead JF; Varghese Z; Tatler GL; Baillod RA; Wills MR
    Ann Clin Biochem; 1975 May; 12(3):126-31. PubMed ID: 15637920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium carbonate as a phosphate binder. One year's experience.
    Kobrin SM; Epstein SE; Goldstein SJ; Kramer MS; Raja RM
    ASAIO Trans; 1987; 33(3):518-20. PubMed ID: 3314935
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence that endogenous calcitonin protects against renal bone disease.
    Kanis JA; Oliver D; Ledingham JC; Russell RG
    Lancet; 1976 Dec; 2(7999):1322-6. PubMed ID: 63802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone and soft tissue changes with oral phosphate supplements.
    Laflamme GH; Jowsey J
    J Clin Invest; 1972 Nov; 51(11):2834-40. PubMed ID: 5080411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Uremic osteodystrophy. Critical evaluation of the radiologic and humoral indices of bone resorption].
    Galmozzi C; Casati S; Rivolta E; De Vecchi A; Imbasciati E; Cecchettin M; Brancaccio D; Ponticelli C
    Minerva Nefrol; 1979; 26(3):405-8. PubMed ID: 262283
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
    Peacock M; Davison AM; Walker GS
    Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of dialysate calcium and fluoride on bone disease during regular hemodialysis.
    Jowsey J; Johnson WJ; Taves DR; Kelly PJ
    J Lab Clin Med; 1972 Feb; 79(2):204-14. PubMed ID: 5009710
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone disease in patients dialyzed with untreated water.
    Rashid A; Posen GA; Gray D; Jaworski ZF
    Med Instrum; 1974; 8(3):204-6. PubMed ID: 4838450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.